DalsnaFinance › Analyst accuracy › Guggenheim › ABSI target
Guggenheim reiterates Absci stock rating on endometriosis trial delay
Guggenheim reiterated a Buy rating and $15.00 price target on Absci Corp.
A fact about what Guggenheim published, as reported by Investing.com, not a recommendation from Dalsna Finance; Guggenheim is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.